[
  {
    "ts": null,
    "headline": "These 3 Stocks Are Healthcare Leaders. Bullish Charts Show It.",
    "summary": "Several non-biotech healthcare stocks are starting to show real momentum, breaking out of bases and asserting themselves as leaders in the sector.  With improving volume patterns, accelerating relative strength, and clean technical setups, this group of medical technology, services, and equipment stocks is quickly becoming one of the strongest pockets in the market.  As buyers rotate toward areas showing sustained upside follow-through, these healthcare names look poised to extend their momentum and deliver standout performance in the weeks ahead.",
    "url": "https://finnhub.io/api/news?id=2717af27688e4e76f1d5e55d3072bb6ad791b313d66d3edfb6f298ba48f4a8bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765298820,
      "headline": "These 3 Stocks Are Healthcare Leaders. Bullish Charts Show It.",
      "id": 137742707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Several non-biotech healthcare stocks are starting to show real momentum, breaking out of bases and asserting themselves as leaders in the sector.  With improving volume patterns, accelerating relative strength, and clean technical setups, this group of medical technology, services, and equipment stocks is quickly becoming one of the strongest pockets in the market.  As buyers rotate toward areas showing sustained upside follow-through, these healthcare names look poised to extend their momentum and deliver standout performance in the weeks ahead.",
      "url": "https://finnhub.io/api/news?id=2717af27688e4e76f1d5e55d3072bb6ad791b313d66d3edfb6f298ba48f4a8bf"
    }
  },
  {
    "ts": null,
    "headline": "Institutional shareholders may be less affected by Abbott Laboratories' (NYSE:ABT) pullback last week after a year of 8.3% returns",
    "summary": "Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...",
    "url": "https://finnhub.io/api/news?id=be32d7b7be19cbcc6ea1aad79aa5adf1e0d50ae0bbe2c7966c240b2157af8f3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765278013,
      "headline": "Institutional shareholders may be less affected by Abbott Laboratories' (NYSE:ABT) pullback last week after a year of 8.3% returns",
      "id": 137740195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...",
      "url": "https://finnhub.io/api/news?id=be32d7b7be19cbcc6ea1aad79aa5adf1e0d50ae0bbe2c7966c240b2157af8f3c"
    }
  },
  {
    "ts": null,
    "headline": "DNA Diagnostics Market Projected to Surge by 66% to USD 21.69 Billion by 2030",
    "summary": "The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of 8.81%. Key trends driving this growth include the emergence of liquid biopsies, the rise of direct-to-consumer testing, the shift to smart bioinformatics, and advancements in genomics and personalized medicine. Increasing genetic disorder prevalence, improved DNA sequencing technology, and expanded diagnostic applications further fuel market expansion. North America leads",
    "url": "https://finnhub.io/api/news?id=8b0b305c14a124e1a2d1312aee5b28ff4f0e6b71de5a8840c54710e31e60afbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765275780,
      "headline": "DNA Diagnostics Market Projected to Surge by 66% to USD 21.69 Billion by 2030",
      "id": 137740196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of 8.81%. Key trends driving this growth include the emergence of liquid biopsies, the rise of direct-to-consumer testing, the shift to smart bioinformatics, and advancements in genomics and personalized medicine. Increasing genetic disorder prevalence, improved DNA sequencing technology, and expanded diagnostic applications further fuel market expansion. North America leads",
      "url": "https://finnhub.io/api/news?id=8b0b305c14a124e1a2d1312aee5b28ff4f0e6b71de5a8840c54710e31e60afbd"
    }
  }
]